Introduction {#S0001}
============

COPD has become the fourth leading cause of death in the world and is expected to become the third by 2020. Potential pathogenic microorganisms (PPM) exist in the lower respiratory tract of patients with stable COPD.[@CIT0001]--[@CIT0003] PPM causes local airway inflammation[@CIT0002],[@CIT0004]--[@CIT0010] and systemic inflammation.[@CIT0005],[@CIT0008],[@CIT0011] PPM is associated with acute exacerbation of COPD,[@CIT0007],[@CIT0009],[@CIT0012] accelerated decline of forced expiratory volume in one second (FEV~1~)[@CIT0013],[@CIT0014] and poor health-related quality of life.[@CIT0008],[@CIT0015]

Researchers have investigated whether antibiotic treatment can alleviate local or systemic inflammation, reduce the rate of acute exacerbation COPD, delay the decline of lung function, and improve the health-related quality of life by reducing the bacterial load or even eradicating PPM. Some studies have shown that antibiotics can reduce local[@CIT0016],[@CIT0017] and systemic inflammation.[@CIT0017] Other studies have not observed these effects on bacterial load,[@CIT0018] airway[@CIT0018],[@CIT0019] or systemic inflammation.[@CIT0019] Nevertheless, long-term macrolide therapy has been found to reduce the times of acute exacerbations of COPD,[@CIT0016],[@CIT0020]--[@CIT0023] improve health-related quality of life.[@CIT0022],[@CIT0023] However, long-term antibiotic use has also been shown to lead to an increase in bacterial resistance[@CIT0018] and hearing loss in some patients.[@CIT0023] Short-term antibiotic therapy can reduce the risk of bacterial resistance and drug-related side effects, but results demonstrating whether it can reduce bacterial load or even eradicate PPM, reduce local or systemic inflammation, and decrease acute exacerbation have been inconsistent.[@CIT0018],[@CIT0019],[@CIT0024]--[@CIT0026]

There are many inflammatory markers that have been used in previous studies to measure systemic inflammation from PPM in stable COPD. The most commonly used markers are serum C-reactive protein (CRP), interleukin-8 (IL-8) and plasma fibrinogen (FIB), but the conclusions from these markers have also been inconsistent. Some studies have found that PPM lead to elevated serum CRP,[@CIT0005] IL-8[@CIT0005] and plasma FIB.[@CIT0008],[@CIT0011] One study found that PPM leads to elevated plasma FIB but not CRP[@CIT0011] In most previous studies examining the effects of antibiotics on inflammation and acute exacerbation of COPD, all patients in the antibiotics groups received antibiotics regardless of the presence or absence of PPM in the lower respiratory tract.[@CIT0016],[@CIT0018]--[@CIT0023] However, PPM negative patients may not benefit from antibiotic therapy. If antibiotics are used indiscriminately, it will increase antibiotic exposure and the risk of antimicrobial resistance. Therefore, the systemic inflammatory markers of PPM and the efficacy of short-term antibiotic therapy need to be further studied. The aim of this study was to further clarify the levels of systemic inflammatory markers in patients with stable COPD and PPM and the impact of short-term antibiotic therapy on these patients.

Methods {#S0002}
=======

Study design and objectives {#S0002-S2001}
---------------------------

From January 2016 to June 2017, patients with a history of COPD were screened. Subjects enrolled were mainly composed of patients who regularly participated in the health education activities of COPD in our department. A diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 criteria was required for eligibility.[@CIT0027] Asthma-COPD overlap syndrome (ACOS) was excluded according to diagnostic criteria. The diagnosis of ACOS needs to meet 2 major criteria and 2 minor criteria. The major criteria included very positive bronchodilator test (increase in FEV~1~ (% predicted) ≥15% and ≥400 ml), eosinophilia in sputum and personal history of asthma before the age of 40. Minor criteria included high total IgE, personal history of atopy and positive bronchodilator test (increase in FEV~1~ (% predicted) ≥12% and ≥200 ml) on two or more occasions.[@CIT0028] Stable COPD was defined as the absence of symptoms of lower respiratory tract infections (increase in dyspnea, cough and/or sputum purulence) within three months prior to inclusion in the study.[@CIT0002] Acute exacerbation of was defined as an acute change of symptoms that were beyond normal day-to-day variation and required a change in daily therapeutic drug regimens.[@CIT0027] All patients had contact numbers registered for both land-line and mobile phone for follow-up interviews. The study protocol was approved by the Ethics Committee of Luhe Hospital, and all patients provided written informed consent. We confirm that this study was based on the Helsinki Declaration.

Inclusion criteria: All patients included in the study met the diagnostic criteria of COPD based on GOLD 2014 criteria (i.e. FEV~1~/FVC \<70% after inhalation of bronchodilator).

Exclusion criteria: Patients were excluded from the study if they had treatment with antibiotics in the past three months; quinolone allergy; immunosuppressive therapy; long-term systemic steroid treatment; history of malignant tumors; or limited activity due to illness.

Primary outcome was systemic inflammation in PPM positive patients with stable COPD.

Secondary outcomes included the effects of PPM on stable COPD patients and the effects of short-term antibiotic therapy on systemic inflammatory markers and acute exacerbation of COPD.

The baseline characteristics of the stable COPD patients were collected on the day of enrollment, including age, sex, smoking status, COPD assessment test (CAT), frequent hospitalization due to acute exacerbation of COPD in the previous year (≥2 times), inhalation drug therapy, domiciliary oxygen therapy, home mechanical ventilation, bronchiectasis, diabetes, coronary heart disease, hypertension, chronic heart failure, chronic renal failure and history of cerebral infarction.

Patients positive for PPM (40) were randomly divided into either the antibiotic group or the control group. The antibiotic group was treated with moxifloxacin 400 mg orally once a day for 6 days, whereas the control group maintained the original treatment with no antibiotic intervention. Lung function and markers of systemic inflammation were measured repeatedly at 30 days and 6 months in PPM positive subjects. The patients enrolled were subject to a follow-up interview by telephone for 12 months. The data collected included the patient's daily treatment, acute exacerbation, and admissions due to acute exacerbation.

Measurements {#S0002-S2002}
------------

The sputum specimens were collected for PPM detection on the day of enrollment. For those patients without existing sputum specimens, 0.9% saline, or 3%, 4% and 5% hypertonic saline were inhaled successively at 7 mins intervals until a qualified sputum specimen was obtained. A volume of 1 mL of sputum volume was required and was immediately sent for examination. Qualified sputum specimens are defined as those specimens with less than 10 epithelial cells and more than 25 white blood cells in the field of low power microscopy.[@CIT0029],[@CIT0030]

Quantitative bacterial cultures from sputum were carried out following accepted laboratory methods.[@CIT0031] PPM is recognized as agent causing respiratory infections included: *Haemophilus* spp., *Moraxella catarrhalis, Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus*, enterobacteria, *Staphylococcus aureus* and others.[@CIT0001],[@CIT0032],[@CIT0033] PPM was considered significant only when the growth was greater than 10^6^ cfu, except from *Streptococcus pneumonia*, where growth greater than 10^5^ cfu was considered adequate.[@CIT0034] Lung function and measurements of CRP, IL-8 and FBI were examined on the day of enrollment. Serum levels of CRP, IL-8, and plasma FIB were determined by latex turbidimetry, chemiluminescence, and immunoturbidimetry, respectively.

Statistical analysis {#S0002-S2003}
--------------------

SPSS version 17.0 for Windows software (SPSS Inc., Chicago, IL, USA) was used for data management and statistical analysis. Continuous variables data were expressed as the mean (SD) or median (range), where as categorical data were presented as a number or percentage. Continuous variables with normal distributions were compared using the parametric unpaired two-independent-group Student\'s *t*-test, whereas those data not normally distributed were compared using the nonparametric Mann-Whitney U-test. Kruskai-Wallis ANOVA and one-way ANOVA were applied to compare the differences of systemic inflammation markers and lung function at the time of enrollment, 30 days and 6 months of follow-up, respectively. Binary logistic regression analysis was used to assess the following risk factors for patients with PPM positive: gender, smoking status, frequent hospitalization in the previous year (≥2 times), age ≥75 ys, bronchiectasis, coronary heart disease, hypertension, diabetes, chronic congestive heart failure, cerebral infarction history, inhaled corticosteroid treatment, domiciliary oxygen therapy, home noninvasive mechanical ventilation treatment, spontaneous sputum, sputum purulence, CAT ≥20 and FEV~1~ (% predicted) \<50%. Calculate the risk factors for odds ratio (OR) and 95% for confidence interval (CI). A Chi-square test was used to compare the counting data. *P*\<0.05 was considered statistically significant.

Sample size estimation: According to Banerjee's study, plasma FIB in 27 PPM positive patients were significantly higher than 40 PPM negative patients.[@CIT0008] In the study of Marin, et al, serum CRP levels in 39 PPM positive patients were higher than those in PPM negative patients.[@CIT0005] Therefore, in order to observe systemic inflammation by these markers, we planned to include 40 PPM positive patients with stable COPD.

Results {#S0003}
=======

A total of 100 stable patients with a history of COPD were screened. Lung function of 96 patients met the diagnostic criteria of COPD for inclusion in our study. Of the 96 patients, 56 were PPM negative and 40 were PPM positive. Forty PPM positive patients were randomly divided into either the antibiotic group (n=20) or the control group (n=20). All 96 patients completed the 12-month follow-up telephone interview; there were no deaths during the follow-up period. ([Figure 1](#F0001){ref-type="fig"})Figure 1Screening, grouping, randomization, and follow-up.**Abbreviations:** COPD, chronic obstructive pulmonary disease; PPM, potentially pathogenic microorganism.

A total of 19 sputum specimens were obtained by saline atomization, 17 cases in PPM negative group and 2 cases in PPM positive group, respectively. Among these 19 cases, only one case had purulent sputum, and the sputum was PPM negative. The other 18 cases had mucous sputum, and only 2 sputum specimens were PPM positive.

We observed no differences between the PPM positive and PPM negative patients when examing for age, sex, smoking status, frequent admissions in the previous year due to acute exacerbation of COPD (≥2 times), comorbidities, domiciliary oxygen therapy, home mechanical ventilation and inhalation drug therapy. We also found that 78.1% (75/96) of the enrolled patients adhered to long-term inhalation therapy. ([Table 1](#T0001){ref-type="table"})Table 1Demographic characteristics and general clinical data of 96 patients with stable COPDCharacteristicsPPM (-)\
(n=56)PPM (+)\
(n=40)*P-*valueAge (years)65.5 (6.7)65.5 (67.5)0.998Male gender (%)48 (85.7)35 (87.5)0.801Ex and current smoking, n (%)50 (89.3)32 (80.0)0.204Frequent admissions in the previous year (≥2), n (%)3 (5.4)3 (7.5)1.000Purulent sputum, n (%)4 (7.3)17 (42.5)0.000Bronchiectasis, n (%)11 (19.6)17 (42.5)0.015Comorbidities Chronic renal failure, n (%)4 (7.1)1 (2.5)0.587 Coronary heart disease, n (%)9 (16.1)8 (20.0)0.619 Hypertension, n (%)29 (52.7)23 (57.5)0.644 Diabetes, n (%)6 (10.7)2 (5.0)0.553 Chronic congestive heart failure, n (%)3 (5.4)7 (17.5)0.114 History of cerebral infarction, n (%)1 (1.8)3 (4.2)0.388 CAT score13.8 (5.1)17.8 (7.7)0.033Lung function FEV~1~ (% pred)50.9 (18.8)44.6 (19.6)0.019 FVC (% pred)64.2 (19.3)60.2 (17.3)0.029 FEV~1~/FVC60.7 (10.7)56.3 (12.3)0.196 Respiratory rate (beat/min)19.6 (1.1)20.0 (1.4)0.374 Heart rate (beat/min)82.6 (6.0)81.4 (7.8)0.141Blood pressure Systolic (mmHg)124.7 (10.6)129.1 (19.2)0.822 Diastolic (mmHg)82.5 (12.7)83.6 (13.3)0.324 Domiciliary oxygen therapy, n (%)12 (26.0)13 (32.5)0.223 Home mechanical ventilation, n (%)1 (1.8)3 (4.2)0.388Inhalation drug therapy ICS ± LABA, n (%)20 (32.5)13 (35.7)0.744 ICS ± LABA ± LAMA, n (%)16 (28.6)16 (40.0)0.242 LAMA, n (%)6 (10.4)4 (10.7)1.000 No inhalation therapy, n (%)14 (25.0)7 (17.5)0.381Systemic inflammation CRP (mg/L)2.8 (1.6--1.6)8.2 (1.6--13.8)0.001 FIB (g/L)7.3 (3.2--11.2)5.8 (3.2--6.6)0.086 IL-8 (pg/mL)19.0 (7.1--13.4)43.2 (9.2--59.6)0.007[^1][^2]

Binary logistic regression analysis showed that risk factors for PPM positive are bronchiectasis (OR 4.18, 95% CI 1.20--14.59; *P*=0.025), CAT ≥20 (OR 17.55, 95% CI 2.82--109.18; *P*=0.002), spontaneous sputum (OR 15.09, 95% CI 1.36--168.02; *P*=0.027) and sputum purulence (OR 38.43, 95% CI 5.39--274.21; *P*=0.000).

CRP and IL-8 were higher in the PPM population than those in the PPM negative population (*P*=0.001, *P*=0.007, respectively), but there were no differences of FIB between the two groups (*P*=0.086). ([Table 1](#T0001){ref-type="table"})

PPM was mainly composed of *Klebsiella pneumoniae* (21 cases) and *Pseudomonas aeruginosa mucosa* (6 cases). Etiology in the antibiotic group consisted of *Klebsiella pneumoniae* (8 cases); *Pseudomonasaeruginosa* (3 cases); *Acinetobacter baumannii* (2 cases); *Pseudomonas oryzae, Pseudomonas putida, Pseudomonas fluorescens, Klebsiella acidogenicus, Pseudomonas maltophilia, Acinetobacter phenanthrene* and *Streptococcus pneumonia* (7 cases, each having one strain). Etiology in control group consisted of *Klebsiella pneumonia* (12 cases) and *Pseudomonas aeruginosa* (3 cases), *Klebsiella acidogenicus, Pseudomonas aeruginosa, Acinetobacter baumannii* and *Enterobacter agglomerates* (4 cases, each having one strain), and one case contained a mixed infection of *Acinetobacter baumannii* and *Klebsiella pneumoniae*.

Follow-up at 12 months: The rate of acute exacerbation of COPD was higher (52.5% vs 30.4%, *P*=0.029), and time to next acute exacerbation was shorter (*P*=0.030), in the PPM positive patients compared to PPM negative patients. There were no differences in the rates of hospitalization and the time to next hospitalization due to acute exacerbation between the PPM negative and PPM positive patients. ([Table 2](#T0002){ref-type="table"})Table 2Comparison of outcomes between the groups of PPM negative and PPM positive12-month telephone follow-upPPM (-)\
(n=56)PPM (+)\
(n=40)*P-*valueAcute exacerbation, n (%)17 (30.4)21 (52.5)0.029Hospitalization due to acute exacerbation, n (%)14 (25.0)16 (40.0)0.118Time to next acute exacerbation (days)191.3 (68.5)135.7 (73.3)0.030Time to next hospitalization (days)192.6 (78.8)148.6 (100.8)0.228[^3][^4]

There were also no differences observed between the antibiotic group and the control group when examined for age, sex, smoking status, frequent hospitalization in the previous year due to acute exacerbation of COPD, bronchiectasis, comorbidities, lung function, inhalation drug therapy, domiciliary oxygen therapy, home mechanical ventilation, CAT score, lung function and systemic inflammatory markers. ([Table 3](#T0003){ref-type="table"})Table 3Demographic characteristics and general clinical data of randomized PPM positive patients with stable COPDCharacteristicsAntibiotic group\
(n=20)Control group\
(n=20)*P-*valueAge (years)66.9 (7.1)65.2 (6.8)0.431Male, n (%)2 (85.0)3 (87.5)1.000Ex and current smoking, n (%)16 (80.0)16 (80.0)1.000Frequent admissions in the previous year (≥2), n (%)1 (5)3 (15)0.605Purulent sputum, n (%)5 (25)3 (15)0.693Domiciliary oxygen therapy, n (%)7 (35)7 (35)1.000Home mechanical ventilation, n (%)2 (10)1 (5)1.000Bronchiectasis, n (%)10 (50.0)7 (35.0)0.337CAT score19.5 (7.2)15.8 (8.1)0.277Lung function FEV~1~ (% pred)43.8 (15.7)45.6 (24.6)0.844 FVC (% pred)59.1 (13.8)61.6 (21.8)0.750 FEV~1~/FVC57.2 (13.2)55.2 (15.6)0.699 Respiratory rate (beat/min)19.5 (1.6)20.1 (1.0)0.314 Heart rate (beat/min)82.0 (4.0)84.2 (6.6)0.371Blood pressure Systolic (mmHg)126.0 (17.0)132.0 (21.1)0.309 Diastolic (mmHg)81.9 (8.9)85.1 (16.6)0.454Inhalation drug therapy ICS ± LABA, n (%)8 (40.0)4 (20.0)0.301ICS ± LABA ± LAMA, n (%)8 (40.0)8 (40.0)1.000 LAMA, n (%)2 (10.0)2 (10.0)1.000 No inhalation therapy, n (%)2 (10.0)6 (30.0)0.236Systemic inflammation CRP (mg/L)6.1 (1.6--9.5)10.8 (1.6--19.3)0.059 FIB (g/L)5.7 (3.1--8.2)5.9 (3.4--5.4)0.156 IL-8 (pg/mL)37.8 (9.0--23.9)50.2 (9.5--74.6)0.204[^5][^6]

Follow-up for 12 months: there were no differences between the antibiotic group and the control group in the rate of acute exacerbation of COPD, the time to the next acute exacerbation and the rate of hospitalization due to acute exacerbation. ([Table 4](#T0004){ref-type="table"})Table 4Comparison of clinical outcomes between patients in PPM negative group and PPM positive group12-month telephone follow-upPPM (-)\
(n=56)PPM (+)\
(n=40)*P-*valueAcute exacerbation, n (%)11(55.0)7(35.0)0.341Hospitalization due to acute exacerbation, n (%)10(50.0)7(35.0)0.523Time to next acute exacerbation (days)181.2 (85.1)199.3 (55.4)0.614Time to next hospitalization (days)172.3 (98.3)210.0 (60.0)0.438[^7][^8]

There were also no differences in lung function and systemic inflammatory markers between the control group and the antibiotic group at the time of enrollment, 30 days and 6 months of follow-up. ([Tables 5](#T0005){ref-type="table"} [and 6](#T0006){ref-type="table"})Table 5Follow-up of CAT, markers for systemic inflammation and lung function in control groupVariablesBaseline30 days follow-up6 months follow-up*P-*valueCAT15.8 (8.1)15.7 (4.3)0.973Systemic inflammation CRP (mg/L)10.8 (1.6--19.3)5.2 (1.6--22.2)10.0 (1.6--30.0)0.583 FIB (g/L)3.8 (3.3--9.1)7.3 (4.1--10.1)9.4 (5.4--11.0)0.087 IL-8 (pg/mL)50.2 (9.5--74.6)18.0 (9.8--74.3)17.1 (7.8--72.1\]0.842Lung function FEV~1~ (% pred)45.6 (24.6)44.2 (22.9)44.9 (22.5)0.991 FVC (% pred)61.6 (21.8)61.7 (20.6)61.9 (19.2)1.000 FEV~1~/FVC55.2 (15.6)52.7 (10.9)55.1 (12.9)0.868[^9][^10] Table 6Follow-up of CAT, markers for systemic inflammation and lung function in the antibiotic groupVariablesBaseline30 days follow-up6 months follow-up*P-*valueCAT19.5 (7.2)15.5 (5.9)0.139Systemic inflammation CRP (mg/L)6.1 (1.6--9.5)3.0 (1.6--1.6)5.5 (1.6--5.8)0.306 FIB (g/L)5.7 (3.1--8.2)4.1 (3.1--3.9)4.9 (3.1--8.8)0.583 IL-8 (pg/mL)37.8 (9.0--23.9)10.1 (5.1--14.6)8.5 (3.5--10.7)0.057Lung function FEV~1~ (% pred)43.8 (15.7)43.0 (15.5)44.8 (14.9)0.951 FVC (% pred)59.1 (13.8)59.7 (14.4)63.2 (11.3)0.711 FEV~1~/FVC57.2 (13.2)57.8 (12.6)57.0 (13.5)0.986[^11][^12]

Discussion {#S0004}
==========

In most studies, the PPM positive cutoff values of quantitative bacteria culture for sputum, Bronchoalveolar lavage fluid (BALF) and protected specimen brush (PSB) were ≥10^6^ cfu,[@CIT0034] ≥10^3^ cfu[@CIT0001],[@CIT0002],[@CIT0009] and ≥10^2^ cfu,[@CIT0001],[@CIT0002],[@CIT0012] respectively. Other studies arbitrary defined the cutoff values of PPM positive for sputum, BALF and PSB as ≥10^2^ cfu,[@CIT0003],[@CIT0005],[@CIT0014],[@CIT0035] ≥10^2^ cfu,[@CIT0006] ≥10^3^ cfu,[@CIT0003] respectively. In some studies, PPM was detected by PCR[@CIT0004],[@CIT0010],[@CIT0015],[@CIT0024],[@CIT0036] or 16S rRNA gene amplification and pyrosequencing.[@CIT0037] Quantitative detection of PPM showed that the rate of PPM positive in stable COPD was 29%\~68%.[@CIT0003],[@CIT0005],[@CIT0006],[@CIT0008],[@CIT0009],[@CIT0011],[@CIT0014],[@CIT0035] The different detection rates of PPM may be related to specimen type, pathogenic detection method, cutoff values of PPM and severity of airflow restriction. Because BALF and PSB are invasive methods of sample collection, and qPCR and 16S rRNA pyrophosphate sequencing are expensive and need high technical expertise, these are not suitable for widespread application in clinical practice. In our study, qualified sputum was spontaneous expectorated or induced by saline inhalation atomization. Quantitative bacterial culture shave been carried out widely in hospitals at different levels. Therefore, our method is easy to implement and disseminate.

Our results showed that the PPM positive rate in stable COPD was 41.7% (40/96), with *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* being the main pathogens present. The composition of the PPM was similar to that of another study in China.[@CIT0010] PPM in European studies is mainly composed of *Haemophilus influenza*[@CIT0004],[@CIT0014],[@CIT0015],[@CIT0035] and *Moraxella catarrhalis*.[@CIT0004],[@CIT0015] This suggests that there are geographical differences in PPM composition in stable COPD, and that there may be differences in inflammatory responses. Some studies found that the decrease of FEV~1~ is related to the increase of airway bacterial load.[@CIT0013] Severe airflow restriction is an independent risk factor for PPM,[@CIT0003] and color of sputum is associated with the presence of PPM.[@CIT0035] In our study, FEV~1~ and FVC were lower in PPM positive group than those in PPM negative group, binary logistic regression analysis showed that bronchiectasis, CAT ≥20, spontaneous sputum and sputum purulence are the risk factors for PPM positive. This indicated that the severity of COPD, sputum purulence and bronchiectasis were closely related to PPM positivity.

Whether CRP can reflect systemic inflammation caused by PPM is inconsistent. Some studies have found that PPM leads to elevated serum CRP, IL-8[@CIT0005] and plasma CRP levels.[@CIT0008],[@CIT0011] In contrast, another study did not find an increase in CRP.[@CIT0011] Our results showed that serum CRP and IL-8 levels were higher in the PPM positive patients than PPM negative patients, whereas no differences in FIB were evident between the two patient populations. These results indicate that CRP and IL-8 were more sensitive indicators of systemic inflammation for stable COPD, PPM positive patients in our study.

Long-term antibiotic therapy can reduce the acute exacerbation of COPD, but can also increase the risk of bacterial resistance. The results of short-term antibiotic therapy for stable COPD have been inconsistent. A few studies have shown that short-term oral antibiotics can reduce airway bacterial load and reduce airway inflammation,[@CIT0026] and even eradicate PPM in a short time, but bacteria quickly re-colonized.[@CIT0024] However, most studies have found that short-term antibiotic therapy does not reduce airway inflammation[@CIT0018],[@CIT0019],[@CIT0025] nor acute exacerbation of COPD,[@CIT0018],[@CIT0025],[@CIT0026] and can even lead to an increase in bacterial resistance.[@CIT0018] In our study, the 12-month follow-up results showed that the rate of acute exacerbation of COPD in the PPM positive patients was higher than that in PPM negative patients. Also, the time to the next acute exacerbation was shorter in PPM positive patients. These results indicate that PPM can cause more acute exacerbation. In order to observe the efficacy of short-term antibiotic treatment in our study, patients with PPM were randomly divided into an antibiotic group and a control group and were followed for 12 months. We found no differences in the rate of acute exacerbation of COPD nor in the time to the next acute exacerbation of COPD between the two groups. The systemic inflammation markers of the two groups also did not change during the follow-up at 6 months. The study results indicate that short-term antibiotic therapy cannot alleviate systemic inflammation and reduce acute exacerbation of COPD.

Our study has some limitations. First, we did not assess airway local airway inflammation and explore the relationship between local and systemic inflammation. Second, during the follow-up period, the number of PPM positive patients who were repeatedly tested for PPM was relatively small. We did not observe dynamic changes of PPM. Finally, future studies will also be needed to detect virus in lower respiratory airways because chronic virus infection can also lead to airway inflammation.[@CIT0038]

Conclusion {#S0005}
==========

PPM exists in the lower respiratory tract in patients with stable COPD that can cause systemic inflammation and lead to an increase in serum CRP and IL-8. PPM is associated with acute exacerbation of COPD. Short-term antibiotic therapy had no effect on systemic inflammation nor acute exacerbation of COPD.
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